Surf Bio is a preclinical biopharmaceutical company founded by the creators of Bigfoot Biomedical and Mode AGC. The company’s core mission is to leverage a breakthrough next-generation surfactant to develop enhanced therapeutic solutions for a range of diseases, including diabetes, oncology, infectious diseases, and gene therapy. Surf Bio aims to address some of the most challenging issues in drug delivery, focusing on creating more effective and stable medicines.
Notable affiliated individuals include the founders of Bigfoot Biomedical and Mode AGC, who bring significant expertise and innovation to the company. Surf Bio has achieved key milestones in the development of its stabilization platform, which promises to revolutionize drug delivery. The company's impact lies in its potential to significantly improve the efficacy and stability of lifesaving medicines across multiple therapeutic areas.
